Maximum Recommended Dose of Verapamil
For intravenous verapamil in adults, the maximum initial bolus is 10 mg (0.15 mg/kg), with a repeat dose of 10 mg after 30 minutes if needed, followed by continuous infusion up to 20 mg/hour; for oral verapamil, the maximum daily dose is 480 mg. 1, 2
Intravenous Administration
Initial Dosing
- Adult initial dose: 5-10 mg (0.075-0.15 mg/kg) administered as an IV bolus over at least 2 minutes under continuous ECG and blood pressure monitoring 3, 1
- Elderly patients: Administer over at least 3 minutes to minimize risk of adverse effects 1
Repeat Dosing
- Second bolus: 10 mg (0.15 mg/kg) may be given 30 minutes after the first dose if initial response is inadequate 3, 1
- This represents the maximum bolus dosing sequence recommended by the FDA 1
Continuous Infusion
- Maintenance infusion: 5 mg/hour, titrated up to a maximum of 20 mg/hour 2
- Alternative dosing: 0.005 mg/kg/min after bolus doses 3
- The infusion should be initiated after bolus administration to maintain therapeutic levels 4
Pediatric IV Dosing
- Ages 0-1 year: 0.1-0.2 mg/kg (usual range 0.75-2 mg) over at least 2 minutes; repeat dose same as initial if needed after 30 minutes 1
- Ages 1-15 years: 0.1-0.3 mg/kg (usual range 2-5 mg) over at least 2 minutes; do not exceed 5 mg single dose initially or 10 mg as a repeat dose 1
Oral Administration
Maximum Daily Dose
- Standard maximum: 480 mg daily (extended-release formulation) 2
- This can be administered as 180-480 mg daily in extended-release form 2
Typical Dosing Range
- Immediate-release: 25-200 mg twice daily (metoprolol comparison suggests similar dosing patterns) 2
- Extended-release: Most commonly dosed between 120-360 mg daily, with maximum of 480 mg 2
- Research supports doses up to 160 mg twice daily (320 mg total) for hypertension management 5
Critical Safety Considerations
Contraindications and Precautions
- Avoid in: AV block greater than first degree, SA node dysfunction without pacemaker, decompensated systolic heart failure, hypotension, cardiogenic shock, and WPW syndrome with atrial fibrillation/flutter 3, 2
- Verapamil causes hypotension, worsening heart failure in patients with pre-existing ventricular dysfunction, and bradycardia 3, 2
Drug Interactions
- P-glycoprotein and CYP3A4 inhibition: Verapamil is a moderate CYP3A4 inhibitor and P-glycoprotein inhibitor, requiring dose adjustments with numerous medications 3
- DOACs: Concomitant use with direct oral anticoagulants increases major bleeding risk (OR 1.38) and GI bleeding risk (OR 1.19) 6
- Contraindicated with dofetilide due to significant drug interaction 3
Administration Details
- IV preparation: Must be given as slow IV injection over at least 2 minutes with continuous ECG and blood pressure monitoring 1
- pH sensitivity: Verapamil precipitates in solutions with pH above 6.0; avoid mixing with albumin, amphotericin B, hydralazine, or trimethoprim-sulfamethoxazole 1
- Stability: Physically compatible for 24 hours at 25°C in most common large volume parenteral solutions when protected from light 1
Pharmacokinetics
- Elimination half-life: IV administration shows bi-exponential elimination with rapid distribution phase (4 minutes) and terminal elimination phase (2-5 hours) 1
- Oral bioavailability: Only 19.4% due to extensive first-pass metabolism 7
- Elderly considerations: Elimination half-life may be prolonged in elderly patients, requiring dose adjustment 1